Articles from Vericel Corporation

Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55%

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025.

Total Revenue Growth of 27% to $57.9 Million

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) --  Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024.

First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration

Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers

CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m. ET on Wednesday, August 14, 2024.

Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million

CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel’s Head of Human Resources since September 2010.

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

Total Revenue Increased 25% to $51.3 Million

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40%

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024.

CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 11:00 a.m. ET (8:00 a.m. PT) on Monday, February 12, 2024.

Full-Year Total Revenue Expected to be Approximately $197.5 Million, Representing 20% Growth, with Fourth Quarter Revenue Growth of 23% to $65 Million

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to begin at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 10, 2024.

Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will present at the Stephens Annual Investment Conference. The fireside chat will begin at 10:00 a.m. ET (9:00 a.m. CT) on Wednesday, November 15, 2023.

CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

Data published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared to Gel Vehicle and standard of care

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference at 7:30 a.m. ET on Tuesday, September 12, 2023.

Record Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year

CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

Record First Quarter Total Revenue of $41 Million

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 12:30 p.m. ET (9:30 a.m. PT) on Tuesday, March 7, 2023.

Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter 2022 financial results on Thursday, February 23, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and certain business highlights.

Full-Year Total Revenue Expected to be Approximately $164 to $165 Million

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to begin at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 11, 2023.

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.

Total Net Product Revenue of $38.6 Million

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and certain business highlights.